1Yamagami T, Arai Y, Matsueda K, et al. The cause of nontumorous defects of portal perfusion in the hepatic hilum revealed by CT during arterial portography. AJR, 1999,172:397-402.
2肝脏超声造影临床应用指南.WFUMB-EFSUMB,2012.
3Yan J,Liu XL,Han LZ,et al.Relation between Ki-67,ER,PR,Her2/neu,p21,EGFR,and TOPⅡ-αexpression in invasive ductal breast cancer patients and correlations with prognosis[J].Asian Pac J Cancer Prev,2015,16(2):823-829.
4Miyake KK,Nakamoto Y,Kanao S,et al.Journal Club:diagnostic value of 18F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer[J].Am J Roentgenol,2014,203(2):272-279.
5Bae MS,Seo M,Kim KG,et al.Quantitative MRI morphology of invasive breast cancer:correlation with immunohistochemical biomarkers and subtypes[J].Acta Radiol,2015,56(3):269-275.
6Verghese ET,Drury R,Green CA,et al.MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion[J].J Pathol,2013,231(3):388-399.
7Suda T,Oba H,Takei H,et al.ER-activating ability of breast cancer stromal fibroblasts is regulated independently of alteration of TP53and PTEN tumor suppressor genes[J].Biochem Biophys Res Commun,2012,428(2):259-263.
8Falchook GS,Moulder SL,Wheler JJ,et al.Dual HER2inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer[J].Ann Oncol,2013,24(12):3004-3011.
9Knoop AS,Lnkholm AV,Jensen MB,et al.Estrogen receptor,progesterone receptor,HER2status and Ki67index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77Ctrial[J].Eur J Cancer,2014,50(8):1412-1421.
